Is Gland Pharma overvalued or undervalued?

As of 31 October 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 41.24, an EV to EBITDA of 21.51, and a PEG ratio of 6.19. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Gland Pharma's PE ratio is significantly higher than Sun Pharma's 35.35 and much greater than Cipla's attractive PE of 22.29. This indicates that Gland Pharma is priced higher relative to its earnings than some of its competitors, which may not justify its current valuation. While Gland Pharma has shown a strong return of 16.79% over the past year compared to the Sensex's 5.73%, the overall valuation metrics suggest that the stock remains overvalued in the current market environment.